FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2014980913> ?p ?o ?g. }

• W2014980913 abstract "Galectins are a family of animal lectins, which bind beta-galactose moieties. Gal3 is the only chimeric family member of Gals and consists of a collagen-like N-terminal region and a C-terminal carbohydrate recognition domain (CRD), which has binding affinity for galactose and N-acetyl-lactosamine. Gal3 is known to be secreted through Golgi apparatus-independent alternative pathway. Previously, we found that stimuli-induced p53 activation induced bystander killing effect against adjacent cells. This p53 bystander effect is mediated through the secretion of Gal3 with the requirement of p53-dependent induction of tumor suppressor activated pathway-6 (TSAP6). We found the apoptotic activity of extracellular Gal3: a variety of tumor cell types (malignant glioma, breast, colon, prostate, lung) are sensitive to Gal3-mediated killing, while normal cells (fibroblast, endothelial) are not affected. We demonstrated that conditional sGal3 induction (tet-on system) in glioma xenografts strongly inhibits tumor growth without overt toxicity in mice. We found that Gal3-mediated tumor cell killing was neutralized with lactose, a Gal3-CRD binding ligand, and Gal3-mediated apoptosis was inhibited by treatment with a caspase 9 inhibitor (LEHD) but not by a caspase 8 inhibitor (IETD). Gal3 interacts with several glycosylated cell surface proteins. We identified that Gal3-induced tumor specific apoptosis is mediated through Gal3-beta1 integrin binding through GST-Gal3 pulldown assay, cell membrane-specific Gal3-beta1 integrin co-immunoprecipitation, and beta1 integrin siRNA neutralization. Further, the treatment of N-glycosylation inhibitor (tunicamycin) interfered with Gal3-beta1 integrin interaction whereas, O-glycosylation inhibitor (benzyl-O-N-acetyl-D-galactosamine) increased N-glycosylation of beta1 integrin as well as consequent Gal3-beta1 integrin interaction and Gal3-mediated apoptosis. In summary, our data demonstrate that extracellular Gal3 interacts with tumor cells through highly-glycosylated cell surface beta1 integrin through its CRD binding and consequently induces apoptosis. These findings are important for our understanding of tumor-specific killing of Gal3 and suggest that Gal3 can be exploited as a therapeutic agent for cancer. Note: This abstract was not presented at the AACR 101st Annual Meeting 2010 because the presenter was unable to attend. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1264." @default.
• W2014980913 created "2016-06-24" @default.
• W2014980913 creator A5000600833 @default.
• W2014980913 creator A5009840937 @default.
• W2014980913 creator A5024318850 @default.
• W2014980913 creator A5078040311 @default.
• W2014980913 date "2010-04-15" @default.
• W2014980913 modified "2023-09-25" @default.
• W2014980913 title "Abstract 1264: Extracellular galectin-3 induces tumor-specific apoptosis through the interaction with highly glycosylated cell surface β1 integrin" @default.
• W2014980913 doi "https://doi.org/10.1158/1538-7445.am10-1264" @default.
• W2014980913 hasPublicationYear "2010" @default.
• W2014980913 type Work @default.
• W2014980913 sameAs 2014980913 @default.
• W2014980913 citedByCount "0" @default.
• W2014980913 crossrefType "proceedings-article" @default.
• W2014980913 hasAuthorship W2014980913A5000600833 @default.
• W2014980913 hasAuthorship W2014980913A5009840937 @default.
• W2014980913 hasAuthorship W2014980913A5024318850 @default.
• W2014980913 hasAuthorship W2014980913A5078040311 @default.
• W2014980913 hasConcept C1491633281 @default.
• W2014980913 hasConcept C153911025 @default.
• W2014980913 hasConcept C185592680 @default.
• W2014980913 hasConcept C195687474 @default.
• W2014980913 hasConcept C55493867 @default.
• W2014980913 hasConcept C86803240 @default.
• W2014980913 hasConcept C95444343 @default.
• W2014980913 hasConceptScore W2014980913C1491633281 @default.
• W2014980913 hasConceptScore W2014980913C153911025 @default.
• W2014980913 hasConceptScore W2014980913C185592680 @default.
• W2014980913 hasConceptScore W2014980913C195687474 @default.
• W2014980913 hasConceptScore W2014980913C55493867 @default.
• W2014980913 hasConceptScore W2014980913C86803240 @default.
• W2014980913 hasConceptScore W2014980913C95444343 @default.
• W2014980913 hasLocation W20149809131 @default.
• W2014980913 hasOpenAccess W2014980913 @default.
• W2014980913 hasPrimaryLocation W20149809131 @default.
• W2014980913 hasRelatedWork W1507708500 @default.
• W2014980913 hasRelatedWork W1540179866 @default.
• W2014980913 hasRelatedWork W1551479053 @default.
• W2014980913 hasRelatedWork W1568242898 @default.
• W2014980913 hasRelatedWork W1922197082 @default.
• W2014980913 hasRelatedWork W2028282027 @default.
• W2014980913 hasRelatedWork W2035135929 @default.
• W2014980913 hasRelatedWork W2041839660 @default.
• W2014980913 hasRelatedWork W2055229669 @default.
• W2014980913 hasRelatedWork W2063352803 @default.
• W2014980913 hasRelatedWork W2068471288 @default.
• W2014980913 hasRelatedWork W2088818435 @default.
• W2014980913 hasRelatedWork W2089002451 @default.
• W2014980913 hasRelatedWork W2093626739 @default.
• W2014980913 hasRelatedWork W2148050927 @default.
• W2014980913 hasRelatedWork W2161346287 @default.
• W2014980913 hasRelatedWork W2188953025 @default.
• W2014980913 hasRelatedWork W2335702252 @default.
• W2014980913 hasRelatedWork W2606262525 @default.
• W2014980913 hasRelatedWork W3043299782 @default.
• W2014980913 isParatext "false" @default.
• W2014980913 isRetracted "false" @default.
• W2014980913 magId "2014980913" @default.
• W2014980913 workType "article" @default.